Cargando…

SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels

OBJECTIVES: It is controversial whether sodium glucose transporter (SGLT) 2 inhibitors increase glucagon secretion via direct inhibition of SGLT2 in pancreatic α cells. The role of SGLT1 in α cells is also unclear. We aimed to elucidate these points that are important not only for basic research but...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suga, Takayoshi, Kikuchi, Osamu, Kobayashi, Masaki, Matsui, Sho, Yokota-Hashimoto, Hiromi, Wada, Eri, Kohno, Daisuke, Sasaki, Tsutomu, Takeuchi, Kazusane, Kakizaki, Satoru, Yamada, Masanobu, Kitamura, Tadahiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323192/ https://www.ncbi.nlm.nih.gov/pubmed/30416006 http://dx.doi.org/10.1016/j.molmet.2018.10.009

Ejemplares similares

The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition
por: Hædersdal, Sofie, et al.
Publicado: (2020)

Protein Kinase C (Pkc)-δ Mediates Arginine-Induced Glucagon Secretion in Pancreatic α-Cells
por: Honzawa, Norikiyo, et al.
Publicado: (2022)

Insulin inhibits glucagon release by SGLT2-induced stimulation of somatostatin secretion
por: Vergari, Elisa, et al.
Publicado: (2019)

A Variation on the Theme: SGLT2 Inhibition and Glucagon Secretion in Human Islets
por: Hodson, David J., et al.
Publicado: (2020)

Kampo medicines, Rokumigan, Hachimijiogan, and Goshajinkigan, significantly inhibit glucagon-induced CREB activation
por: Funakoshi-Tago, Megumi, et al.
Publicado: (2020)

Effect of Sodium Glucose Cotransporter 2 Inhibitors With Low SGLT2/SGLT1 Selectivity on Circulating Glucagon-Like Peptide 1 Levels in Type 2 Diabetes Mellitus
por: Takebayashi, Kohzo, et al.
Publicado: (2017)

Neuronal SIRT1 regulates macronutrient-based diet selection through FGF21 and oxytocin signalling in mice
por: Matsui, Sho, et al.
Publicado: (2018)

Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors
por: Alatrach, Mariam, et al.
Publicado: (2020)

The Potential of Hibiscus sabdariffa Linn in Inducing Glucagon-Like Peptide-1 via SGLT-1 and GLPR in DM Rats
por: Kartinah, Neng Tine, et al.
Publicado: (2019)

Disparities in the Use of SGLT2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Adults With CKD in the United States
por: Nicholas, Susanne B., et al.
Publicado: (2022)

A central-acting connexin inhibitor, INI-0602, prevents high-fat diet-induced feeding pattern disturbances and obesity in mice
por: Sasaki, Tsutomu, et al.
Publicado: (2018)

Anti-inflammatory and atheroprotective properties of glucagon
por: Osaka, Naoya, et al.
Publicado: (2020)

SGLT2 is not expressed in pancreatic α- and β-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans
por: Chae, Heeyoung, et al.
Publicado: (2020)

Disparities in SGLT2 Inhibitor or Glucagon-Like Peptide 1 Receptor Agonist Initiation Among Medicare-Insured Adults With CKD in the United States
por: Zhao, Julie Z., et al.
Publicado: (2022)

Glucagon Receptor Signaling and Glucagon Resistance
por: Janah, Lina, et al.
Publicado: (2019)

Hypoglycemia Risk With SGLT2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists Versus Sulfonylureas Among Medicare Insured Adults With CKD in the United States
por: Zhao, Julie Z., et al.
Publicado: (2022)

Ipragliflozin-induced improvement of liver steatosis in obese mice may involve sirtuin signaling
por: Suga, Takayoshi, et al.
Publicado: (2020)

SGLT2 and cancer
por: Wright, Ernest M.
Publicado: (2020)

Novel natural and synthetic inhibitors of solute carriers SGLT1 and SGLT2
por: Oranje, Paul, et al.
Publicado: (2019)

Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem
por: Vallianou, Natalia G., et al.
Publicado: (2021)

Pseudo‐hyperglucagonemia was observed in pancreatectomized patients when measured by glucagon sandwich enzyme‐linked immunosorbent assay
por: Kobayashi, Masaki, et al.
Publicado: (2020)

SGLT Gene Expression in Primary Lung Cancers and Their Metastatic Lesions
por: Ishikawa, Nobuhisa, et al.
Publicado: (2001)

Insulin stimulates SGLT2-mediated tubular glucose absorption via oxidative stress generation
por: Nakamura, Nobutaka, et al.
Publicado: (2015)

SGLT1 and SGLT1 Inhibitors: A Role to Be Assessed in the Current Clinical Practice
por: Spatola, Leonardo, et al.
Publicado: (2017)

Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2
por: Ghezzi, Chiara, et al.
Publicado: (2018)

Effects of SGLT2 Inhibitors beyond Glycemic Control—Focus on Myocardial SGLT1
por: Sayour, Alex Ali, et al.
Publicado: (2021)

Mechanistic evaluation of the inhibitory effect of four SGLT-2 inhibitors on SGLT 1 and SGLT 2 using physiologically based pharmacokinetic (PBPK) modeling approaches
por: Zhang, Yu, et al.
Publicado: (2023)

Stability of glucagon-like peptide 1 and glucagon in human plasma
por: Wewer Albrechtsen, Nicolai J, et al.
Publicado: (2015)

Sirt1 rescues the obesity induced by insulin-resistant constitutively-nuclear FoxO1 in POMC neurons of male mice
por: Susanti, Vina Yanti, et al.
Publicado: (2014)

Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF
por: Bode, David, et al.
Publicado: (2021)

A newly developed glucagon sandwich ELISA is useful for more accurate glucagon evaluation than the currently used sandwich ELISA in subjects with elevated plasma proglucagon‐derived peptide levels
por: Kobayashi, Masaki, et al.
Publicado: (2023)

SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy
por: Kawanami, Daiji, et al.
Publicado: (2017)

Evaluation of commercially available glucagon receptor antibodies and glucagon receptor expression
por: Bomholt, Anna Billeschou, et al.
Publicado: (2022)

Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
por: Wicik, Zofia, et al.
Publicado: (2022)

Does SGLT1 inhibition add to the benefits of SGLT2 inhibition in the prevention and treatment of heart failure?
por: Pitt, Bertram, et al.
Publicado: (2022)

Mouse Models with SGLT2 Mutations: Toward Understanding the Role of SGLT2 beyond Glucose Reabsorption
por: Unno, Keiko, et al.
Publicado: (2023)

Glucagon : its role in physiology and clinical medicine
Publicado: (1977)

The new type 2 diabetes mellitus therapy: comparison between the two classes of drugs GLPR (glucagon-like peptide receptor) agonists and SGLT2 (sodium–glucose cotransporter 2) inhibitors
por: Borghi, Claudio, et al.
Publicado: (2020)

Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)
por: Gourdy, Pierre, et al.
Publicado: (2023)

The anti-inflammatory effects of SGLT inhibitors
por: García-Ropero, Álvaro, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kd3eg3p3jv1f8sq84gqt8pvuc2